Navigation Links
Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties
Date:9/28/2010

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists will be the most aggressive in adopting biosimilars compared with other specialties because of their lower clinical trial requirements. According to Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology, Decision Resources expects biosimilar versions of granulocyte colony-stimulating factor (G-CSF) and monoclonal antibody (MAb) therapies used in oncology to erode more than $7 billion in brand sales in 2019 alone across the U.S., EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan markets.

Primary research reveals U.S oncologists in particular will more rapidly adopt biosimilars compared to their European counterparts. Compared with French and German oncologists, U.S. oncologists will require fewer and shorter Phase III clinical trials before they feel comfortable prescribing biosimilars. The majority of surveyed U.S. oncologists would require one trial lasting 12 months or less for biosimilar G-CSFs and at most two clinical trials lasting two years or less for biosimilar MAbs before they feel comfortable prescribing biosimilars. Surveyed solid-tumor oncologists across countries have higher expectations for clinical trials of biosimilar MAbs than for biosimilar G-CSFs.

Across the U.S., France and Germany, the majority of surveyed oncologists expect to begin prescribing biosimilars within 12 months after launch, contributing to the rapid erosion of branded G-CSFs and MAbs.

"Because of patent expiries and more established regulatory pathways for approving biosimilars in Europe, most biosimilar MAbs will launch in the EU5 before the United States," said Decision Resources Analyst Cindy Fung, Ph.D. "As a result, U.S. physicians will likely benefit from clinical experience in European markets that will increase their rate of adopting these agents."

The Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German solid-tumor oncologists and hematologist-oncologists to highlight the key expectations that will drive or constrain biosimilar adoption.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.For more information, contact:Decision ResourcesLisa Osgood781-993-2606losgood@dresources.com   Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
4. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
5. Society of Gynecologic Oncologists 40th Annual Meeting on Womens Cancer to Include Sessions on Robotics Surgery
6. SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists
7. Society of Gynecologic Oncologists Issues White Paper on HPV Vaccines Impact on Cervical Cancer Prevention
8. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
9. US Oncology Launches New Flexible Options for Community Oncologists to Join the United Network of US Oncology
10. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  CTI BioPharma Corp. (CTI ... plans to report its fourth quarter and full year ... close of the U.S. financial markets. Following the announcement, ... conference call to discuss the results and provide a ... to the event can be obtained as follows: ...
(Date:2/22/2017)... NORTHVALE, N.J. , Feb. 22, 2017  Andre, ... a technology-based developer and manufacturer of innovative technologies and ... financial results reported on February 21, 2017 in the ... www.sec.gov . ADMT CEO Andre, DiMino stated ... with our business plan by devoting a larger portion ...
(Date:2/22/2017)... -- Ultra Clean Holdings, Inc. (Nasdaq: UCTT), a leading ... for the semiconductor capital equipment, flat panel, medical, ... results for the fourth quarter and fiscal year ... a year of extraordinary growth for UCT. Total ... together with continued focus on operational excellence resulted ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... Our high-octane society demands higher stands ... brain. , Power On, a mental performance enhancer from Modus Nutrition, provides scientifically ... capsule contains Cognizin® Citicoline, a branded form of the brain health nutrient citicoline ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The ... to the thousands of individuals who have recently fallen victim to America’s opioid epidemic. ... in Orange County, California, where they are free from the shame, stigma, and ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the award-winning TV series that ... On The Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, ... ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish with war veteran Justin ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... ... 22, 2017 , ... Sideline Products participated in the World Horse Expo held ... Seay and his production crew. Tom Seay’s program “Best of America by Horseback” ... Saddle Sidekicks will be featured on April 6, 2017. After the broadcast, the clip ...
Breaking Medicine News(10 mins):